Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Discovery of Potent and Selective Next-Generation Pan-BCR-ABL Inhibitors for the Treatment of CML and Ph+ ALL

Yun Zhang, Sara Nadworny, Shengwu Liu, Sen Zhang, Emily Ye, Narayana Narasimhan, David C Dalgarno, Justin Pritchard, Wei-Sheng Huang, William C Shakespeare, Victor M Rivera

Blood (2023) 142 (Supplement 1): 1428.

https://doi.org/10.1182/blood-2023-172982

Published: 2023

Journal Articles

Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Kristy Drafahl, David C Smith, Cristen Graham, Christine Glynn, Cindy Spittle, Scott Verrow, Victor M. Rivera, PhD, Shouryadeep Srivastava, MBBS, PhD, Kevin Hawkins, Chad Galderisi, DO

Blood (2018) 132 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2018-99-113172

Published: 2018

Journal Articles

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Blood (2018) 132 (4): 393–404.

https://doi.org/10.1182/blood-2016-09-739086

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Blood (2017) 130 (Supplement 1): 1617.

https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617

Published: 2017

Journal Articles

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial

Michael J. Mauro, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil P. Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Victor M. Rivera, PhD, Stephanie Lustgarten, PhD, Sergio Santillana, MD, Michael C. Heinrich, Brian J. Druker, MD, Michael W. Deininger, MD PhD, Moshe Talpaz, MD

Blood (2016) 128 (22): 3063.

https://doi.org/10.1182/blood.V128.22.3063.3063

Published: 2016

Journal Articles

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Elias J. Jabbour, MD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Michele Baccarani, MD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Francois Guilhot, MD, Michael W. Deininger, MD PhD, Neil Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Sergio Santillana, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 3067.

https://doi.org/10.1182/blood.V128.22.3067.3067

Published: 2016

Journal Articles

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Justin R. Pritchard, PhD, Michael W. Schmitt, MD PhD, J. Graeme Hodgson, PhD, Stephanie Lustgarten, PhD, Shijie Tang, PhD, Lawrence A. Loeb, MD PhD, Jerald P. Radich, MD, Victor M. Rivera, PhD

Blood (2016) 128 (22): 1061.

https://doi.org/10.1182/blood.V128.22.1061.1061

Published: 2016

Journal Articles

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

Wendy T. Parker, David T. O. Yeung, Alexandra L. Yeoman, Haley K. Altamura, Bronte A. Jamison, Chani R. Field, J. Graeme Hodgson, Stephanie Lustgarten, Victor M. Rivera, Timothy P. Hughes, Susan Branford

Blood (2016) 127 (15): 1870–1880.

https://doi.org/10.1182/blood-2015-09-666214

Published: 2016

Includes: Supplemental data

Journal Articles

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Blood (2016) 127 (6): 703–712.

https://doi.org/10.1182/blood-2015-08-660977

Published: 2016

Includes: Supplemental data

Journal Articles

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Michael W. Schmitt, MD PhD, Justin R. Pritchard, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Bella I. Aminov, Lan Beppu, Lawrence A. Loeb, MD PhD, Jerald P. Radich

Blood (2015) 126 (23): 478.

https://doi.org/10.1182/blood.V126.23.478.478

Published: 2015

Journal Articles

A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients

Victor M. Rivera, Susan Branford, Franck E. Nicolini, Justin R. Pritchard, Joseph M. Gozgit, Wolfgang Kern, MD, Dragana Milojkovic, Simone Claudiani, Martin C. Muller, Srinivas K Tantravahi, Michael W. Deininger, Michael Heinrich, Simona Soverini, Michele Baccarani, Jerald P. Radich, Elias Jabbour, Jorge E. Cortes, Gabriel Etienne, Torsten Haferlach

Blood (2015) 126 (23): 2790.

https://doi.org/10.1182/blood.V126.23.2790.2790

Published: 2015

Journal Articles

Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models

Joseph M. Gozgit, Youngchul Song, Scott Wardwell, Sara Nadworny, Yaoyu Ning, Victor M. Rivera

Blood (2015) 126 (23): 4000.

https://doi.org/10.1182/blood.V126.23.4000.4000

Published: 2015

Journal Articles

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Blood (2015) 126 (23): 4025.

https://doi.org/10.1182/blood.V126.23.4025.4025

Published: 2015

Journal Articles

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Justin R. Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, MD, Jorge E. Cortes, MD, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Tim Clackson, Frank G. Haluska, Ronald Knickerbocker, Victor M. Rivera

Blood (2014) 124 (21): 3153.

https://doi.org/10.1182/blood.V124.21.3153.3153

Published: 2014

Journal Articles

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Blood (2014) 124 (21): 3135.

https://doi.org/10.1182/blood.V124.21.3135.3135

Published: 2014

Journal Articles

Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials

Michael J. Mauro, Jorge E. Cortes, MD, Andreas Hochhaus, Michele Baccarani, Timothy P. Hughes, Francois Guilhot, Michael W. Deininger, Hagop M. Kantarjian, Neil P. Shah, Dale Bixby, Ian Flinn, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, Tim Clackson, Moshe Talpaz

Blood (2014) 124 (21): 4552.

https://doi.org/10.1182/blood.V124.21.4552.4552

Published: 2014

Journal Articles

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Moshe Talpaz, Jorge E. Cortes, Hagop Kantarjian, Neil P. Shah, Dale Bixby, Ian Flinn, Thomas O'Hare, PhD, Simin Hu, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Brian J. Druker, Michael W. Deininger, Michael J. Mauro, MD

Blood (2014) 124 (21): 4558.

https://doi.org/10.1182/blood.V124.21.4558.4558

Published: 2014

Journal Articles

Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib

Martin C. Mueller, Michele Baccarani, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Frank G. Haluska, Jorge E. Cortes, MD

Blood (2014) 124 (21): 518.

https://doi.org/10.1182/blood.V124.21.518.518

Published: 2014

Journal Articles

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

Blood (2014) 124 (21): 519.

https://doi.org/10.1182/blood.V124.21.519.519

Published: 2014

Journal Articles

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Victor M. Rivera, PhD, Justin R. Pritchard, PhD, Francois Gonzalvez, PhD, Theresa Baker, Joseph M. Gozgit, PhD, Graeme Hodgson, PhD

Blood (2014) 124 (21): 1783.

https://doi.org/10.1182/blood.V124.21.1783.1783

Published: 2014

NARROW

Discovery of Potent and Selective Next-Generation Pan-BCR-ABL Inhibitors for the Treatment of CML and Ph+ ALL

Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients

Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only